Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome
Identifieur interne : 000340 ( Main/Corpus ); précédent : 000339; suivant : 000341Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome
Auteurs : Lukas J. KappenbergerSource :
- Clinical Progress in Electrophysiology and Pacing [ 8756-9264 ] ; 1986-12.
English descriptors
- KwdEn :
Abstract
The ayitiarrhythmic properties of amiodarone in WPW‐syndrome depend on several simultaneously active mechanisms. Its electrophysiologic properties lead to reduction of excitabUity, lengthening of refractory periods and slowing of conduction. With these effects, it reduces premature ectopic beats and thus initiating events for tachycardias. The ventricular response during atrial fibrillation will be reduced in most but unfor‐tunately not all patients and tachycardia cycle length will be prolonged. Therefore amiodarone seems to be the drug of choice in WPW‐syndrome if there was not a high incidence of side‐effects and an extremely long tissue half‐life. The prescription has therefore to be made with caution since if once applied, its effects are not immediately renersible. Hoioever, in some cases it offers an alternative for surgery of IVPW.
Url:
DOI: 10.1111/j.1540-8167.1986.tb01727.x
Links to Exploration step
ISTEX:F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome</title><author><name sortKey="Kappenberger, Lukas J" sort="Kappenberger, Lukas J" uniqKey="Kappenberger L" first="Lukas J." last="Kappenberger">Lukas J. Kappenberger</name><affiliation><mods:affiliation>From the Division of Cardiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8</idno><date when="1986" year="1986">1986</date><idno type="doi">10.1111/j.1540-8167.1986.tb01727.x</idno><idno type="url">https://api.istex.fr/document/F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000340</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome</title><author><name sortKey="Kappenberger, Lukas J" sort="Kappenberger, Lukas J" uniqKey="Kappenberger L" first="Lukas J." last="Kappenberger">Lukas J. Kappenberger</name><affiliation><mods:affiliation>From the Division of Cardiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Progress in Electrophysiology and Pacing</title><idno type="ISSN">8756-9264</idno><idno type="eISSN">1540-8167</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1986-12">1986-12</date><biblScope unit="volume">4</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="499">499</biblScope><biblScope unit="page" to="507">507</biblScope></imprint><idno type="ISSN">8756-9264</idno></series><idno type="istex">F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8</idno><idno type="DOI">10.1111/j.1540-8167.1986.tb01727.x</idno><idno type="ArticleID">JCE499</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">8756-9264</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Accessory pathway</term><term>Kent bundle</term><term>atrial fibrillation</term><term>drug interaction</term><term>hemodynamics</term><term>supraventricular tachycardia</term><term>ventricular ectopy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The ayitiarrhythmic properties of amiodarone in WPW‐syndrome depend on several simultaneously active mechanisms. Its electrophysiologic properties lead to reduction of excitabUity, lengthening of refractory periods and slowing of conduction. With these effects, it reduces premature ectopic beats and thus initiating events for tachycardias. The ventricular response during atrial fibrillation will be reduced in most but unfor‐tunately not all patients and tachycardia cycle length will be prolonged. Therefore amiodarone seems to be the drug of choice in WPW‐syndrome if there was not a high incidence of side‐effects and an extremely long tissue half‐life. The prescription has therefore to be made with caution since if once applied, its effects are not immediately renersible. Hoioever, in some cases it offers an alternative for surgery of IVPW.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>LUKAS J. KAPPENBERGER</name><affiliations><json:string>From the Division of Cardiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Accessory pathway</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>atrial fibrillation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>drug interaction</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hemodynamics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Kent bundle</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>supraventricular tachycardia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ventricular ectopy</value></json:item></subject><articleId><json:string>JCE499</json:string></articleId><language><json:string>eng</json:string></language><abstract>The ayitiarrhythmic properties of amiodarone in WPW‐syndrome depend on several simultaneously active mechanisms. Its electrophysiologic properties lead to reduction of excitabUity, lengthening of refractory periods and slowing of conduction. With these effects, it reduces premature ectopic beats and thus initiating events for tachycardias. The ventricular response during atrial fibrillation will be reduced in most but unfor‐tunately not all patients and tachycardia cycle length will be prolonged. Therefore amiodarone seems to be the drug of choice in WPW‐syndrome if there was not a high incidence of side‐effects and an extremely long tissue half‐life. The prescription has therefore to be made with caution since if once applied, its effects are not immediately renersible. Hoioever, in some cases it offers an alternative for surgery of IVPW.</abstract><qualityIndicators><score>6.941</score><pdfVersion>1.6</pdfVersion><pdfPageSize>613 x 874 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>7</keywordCount><abstractCharCount>851</abstractCharCount><pdfWordCount>3965</pdfWordCount><pdfCharCount>26815</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>123</abstractWordCount></qualityIndicators><title>Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome</title><genre><json:string>article</json:string></genre><host><volume>4</volume><publisherId><json:string>JCE</json:string></publisherId><pages><total>9</total><last>507</last><first>499</first></pages><issn><json:string>8756-9264</json:string></issn><issue>6</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1540-8167</json:string></eissn><title>Clinical Progress in Electrophysiology and Pacing</title><doi><json:string>10.1111/(ISSN)1540-8167b</json:string></doi></host><publicationDate>1986</publicationDate><copyrightDate>1986</copyrightDate><doi><json:string>10.1111/j.1540-8167.1986.tb01727.x</json:string></doi><id>F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1986</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome</title><author><persName><forename type="first">LUKAS J.</forename><surname>KAPPENBERGER</surname></persName><note type="correspondence"><p>Correspondence: Address for reprints: Prof. L. Kappenberger, Division de Cardiologie, Centre Hospitalier Universitaire Vaudois, CH‐1011 Lausanne, Switzerland.</p></note><affiliation>From the Division of Cardiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland</affiliation></author></analytic><monogr><title level="j">Clinical Progress in Electrophysiology and Pacing</title><idno type="pISSN">8756-9264</idno><idno type="eISSN">1540-8167</idno><idno type="DOI">10.1111/(ISSN)1540-8167b</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1986-12"></date><biblScope unit="volume">4</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="499">499</biblScope><biblScope unit="page" to="507">507</biblScope></imprint></monogr><idno type="istex">F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8</idno><idno type="DOI">10.1111/j.1540-8167.1986.tb01727.x</idno><idno type="ArticleID">JCE499</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1986</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The ayitiarrhythmic properties of amiodarone in WPW‐syndrome depend on several simultaneously active mechanisms. Its electrophysiologic properties lead to reduction of excitabUity, lengthening of refractory periods and slowing of conduction. With these effects, it reduces premature ectopic beats and thus initiating events for tachycardias. The ventricular response during atrial fibrillation will be reduced in most but unfor‐tunately not all patients and tachycardia cycle length will be prolonged. Therefore amiodarone seems to be the drug of choice in WPW‐syndrome if there was not a high incidence of side‐effects and an extremely long tissue half‐life. The prescription has therefore to be made with caution since if once applied, its effects are not immediately renersible. Hoioever, in some cases it offers an alternative for surgery of IVPW.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Accessory pathway</term></item><item><term>atrial fibrillation</term></item><item><term>drug interaction</term></item><item><term>hemodynamics</term></item><item><term>Kent bundle</term></item><item><term>supraventricular tachycardia</term></item><item><term>ventricular ectopy</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1986-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1540-8167b</doi><issn type="print">8756-9264</issn><issn type="electronic">1540-8167</issn><idGroup><id type="product" value="JCE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="CLINICAL PROGRESS IN ELECTROPHYSIOLOGY AND PACING">Clinical Progress in Electrophysiology and Pacing</title></titleGroup></publicationMeta><publicationMeta level="part" position="12106"><doi origin="wiley">10.1111/jce.1986.4.issue-6</doi><numberingGroup><numbering type="journalVolume" number="4">4</numbering><numbering type="journalIssue" number="6">6</numbering></numberingGroup><coverDate startDate="1986-12">December 1986</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0049900" status="forIssue"><doi origin="wiley">10.1111/j.1540-8167.1986.tb01727.x</doi><idGroup><id type="unit" value="JCE499"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><eventGroup><event type="firstOnline" date="2008-06-28"></event><event type="publishedOnlineFinalForm" date="2008-06-28"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:3.2.3 mode:FullText" date="2013-08-15"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-29"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-17"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="499">499</numbering><numbering type="pageLast" number="507">507</numbering></numberingGroup><correspondenceTo>Address for reprints: Prof. L. Kappenberger, Division de Cardiologie, Centre Hospitalier Universitaire Vaudois, CH‐1011 Lausanne, Switzerland.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JCE.JCE499.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="referenceTotal" number="45"></count><count type="linksCrossRef" number="2"></count></countGroup><titleGroup><title type="main">Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>LUKAS J.</givenNames><familyName>KAPPENBERGER</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="CH"><unparsedAffiliation>From the Division of Cardiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Accessory pathway</keyword><keyword xml:id="k2">atrial fibrillation</keyword><keyword xml:id="k3">drug interaction</keyword><keyword xml:id="k4">hemodynamics</keyword><keyword xml:id="k5">Kent bundle</keyword><keyword xml:id="k6">supraventricular tachycardia</keyword><keyword xml:id="k7">ventricular ectopy</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>The ayitiarrhythmic properties of amiodarone in WPW‐syndrome depend on several simultaneously active mechanisms. Its electrophysiologic properties lead to reduction of excitabUity, lengthening of refractory periods and slowing of conduction. With these effects, it reduces premature ectopic beats and thus initiating events for tachycardias. The ventricular response during atrial fibrillation will be reduced in most but unfor‐tunately not all patients and tachycardia cycle length will be prolonged. Therefore amiodarone seems to be the drug of choice in WPW‐syndrome if there was not a high incidence of side‐effects and an extremely long tissue half‐life. The prescription has therefore to be made with caution since if once applied, its effects are not immediately renersible. Hoioever, in some cases it offers an alternative for surgery of IVPW.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome</title></titleInfo><name type="personal"><namePart type="given">LUKAS J.</namePart><namePart type="family">KAPPENBERGER</namePart><affiliation>From the Division of Cardiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland</affiliation><description>Correspondence: Address for reprints: Prof. L. Kappenberger, Division de Cardiologie, Centre Hospitalier Universitaire Vaudois, CH‐1011 Lausanne, Switzerland.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1986-12</dateIssued><copyrightDate encoding="w3cdtf">1986</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">45</extent></physicalDescription><abstract lang="en">The ayitiarrhythmic properties of amiodarone in WPW‐syndrome depend on several simultaneously active mechanisms. Its electrophysiologic properties lead to reduction of excitabUity, lengthening of refractory periods and slowing of conduction. With these effects, it reduces premature ectopic beats and thus initiating events for tachycardias. The ventricular response during atrial fibrillation will be reduced in most but unfor‐tunately not all patients and tachycardia cycle length will be prolonged. Therefore amiodarone seems to be the drug of choice in WPW‐syndrome if there was not a high incidence of side‐effects and an extremely long tissue half‐life. The prescription has therefore to be made with caution since if once applied, its effects are not immediately renersible. Hoioever, in some cases it offers an alternative for surgery of IVPW.</abstract><subject lang="en"><genre>Keywords</genre><topic>Accessory pathway</topic><topic>atrial fibrillation</topic><topic>drug interaction</topic><topic>hemodynamics</topic><topic>Kent bundle</topic><topic>supraventricular tachycardia</topic><topic>ventricular ectopy</topic></subject><relatedItem type="host"><titleInfo><title>Clinical Progress in Electrophysiology and Pacing</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">8756-9264</identifier><identifier type="eISSN">1540-8167</identifier><identifier type="DOI">10.1111/(ISSN)1540-8167b</identifier><identifier type="PublisherID">JCE</identifier><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>499</start><end>507</end><total>9</total></extent></part></relatedItem><identifier type="istex">F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8</identifier><identifier type="DOI">10.1111/j.1540-8167.1986.tb01727.x</identifier><identifier type="ArticleID">JCE499</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000340 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000340 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:F9CB6FFE1A1B4EC46135E2B55E4F434FD817B9F8
|texte= Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |